secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035656
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome CRESCENDO survey: 77% of treated NT1 patients still have cataplexy; 74% cognitive impairment
--------------------------------------------------------------------------------

- 77% of treated NT1 patients continue to experience cataplexy attacks despite current therapy.
- 64% have excessive daytime sleepiness (ESS>10); 74% exhibit cognitive impairment (BC-CCI≥5).
- Depression and anxiety reported by 45% and 57% of patients, respectively.
- Survey included 203 adults; top treatments were wake-promoting agents (53%), oxybates (47%), stimulants (42%).
- Axsome plans to present detailed CRESCENDO results at upcoming scientific meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/0000950170-24-035656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/axsm-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer